相似文献
1
Making decisions about benefits and harms of medicines.
BMJ. 2004 Jul 3;329(7456):47-50. doi: 10.1136/bmj.329.7456.47.
2
Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Drug Saf. 2011 Mar 1;34(3):187-97. doi: 10.2165/11586620-000000000-00000.
3
Strategy in Regulatory Decision-Making for Management of Progressive Multifocal Leukoencephalopathy.
Clin Pharmacol Ther. 2015 Nov;98(5):502-5. doi: 10.1002/cpt.199. Epub 2015 Sep 11.
4
Good decision making requires good communication.
Drug Saf. 2012 Nov 1;35(11):983-93. doi: 10.1007/BF03261986.
5
Primum non nocere.
JAMA. 1977 Aug 15;238(7):589-90.
6
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):667-78. doi: 10.1002/pds.3636. Epub 2014 May 13.
7
Improving the Safety of Medicines in the European Union: From Signals to Action.
Clin Pharmacol Ther. 2020 Mar;107(3):521-529. doi: 10.1002/cpt.1678. Epub 2019 Dec 6.
8
Balancing risks versus benefits in drug therapy decisions.
Clin Ther. 1998;20 Suppl C:C72-9. doi: 10.1016/s0149-2918(98)80010-6.
9
Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
Clin Pharmacol Ther. 2022 Jan;111(1):35-43. doi: 10.1002/cpt.2410. Epub 2021 Sep 18.
10
[The new pharmacovigilance legislation in practice].
Ned Tijdschr Geneeskd. 2014;158:A7129.
引用本文的文献
1
Interventions that challenge established and accepted clinical practice: lessons learnt from a process evaluation of the STOP-APE trial.
Health Technol Assess. 2025 Feb;29(11):1-11. doi: 10.3310/PSDG7298.
2
Why Oncology Global Safety Teams Should Develop the Safety Section of the Study's Target Product Profile (TPP).
Pharmaceut Med. 2024 Mar;38(2):97-108. doi: 10.1007/s40290-024-00516-z. Epub 2024 Feb 27.
3
Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics.
Antibiotics (Basel). 2022 Mar 25;11(4):445. doi: 10.3390/antibiotics11040445.
4
Evaluation of adverse drug reaction formatting in drug information mobile phone applications.
J Med Libr Assoc. 2022 Jan 1;110(1):81-86. doi: 10.5195/jmla.2022.1251.
5
Pharmacokinetics and Perceptions of Children and Young Adults Using Cannabis for Attention-Deficit/Hyperactivity Disorder and Oppositional Defiant Disorder: Protocol for a Mixed Methods Proof-of-Concept Study.
JMIR Res Protoc. 2021 Oct 18;10(10):e31281. doi: 10.2196/31281.
6
Adverse drug reactions in drug information databases: does presentation affect interpretation?
J Med Libr Assoc. 2020 Jan;108(1):76-83. doi: 10.5195/jmla.2020.748. Epub 2020 Jan 1.
7
Is There a Tension between Clinical Practice and Reimbursement Policy? The Case of Osteoarthritis Prescribing Practices in Ontario.
Healthc Policy. 2007 Nov;3(2):e128-44.
8
A strategy for regulatory action when new adverse effects of a licensed product emerge.
Drug Saf. 2009;32(2):91-8. doi: 10.2165/00002018-200932020-00002.
9
Homeless drug users' awareness and risk perception of peer "take home naloxone" use--a qualitative study.
Subst Abuse Treat Prev Policy. 2006 Oct 2;1:28. doi: 10.1186/1747-597X-1-28.
10
[Values and preferences of patients: question pending].
Aten Primaria. 2005 Apr 30;35(7):379. doi: 10.1157/13074300.
本文引用的文献
1
Pharmacogenetics--expectations and reality.
BMJ. 2004 Jul 3;329(7456):4-6. doi: 10.1136/bmj.329.7456.4.
2
Informed choice and balance are victims of the MMR-autism saga.
Lancet Infect Dis. 2004 Mar;4(3):135-6. doi: 10.1016/S1473-3099(04)00934-X.
3
Why do doctors use treatments that do not work?
BMJ. 2004 Feb 28;328(7438):474-5. doi: 10.1136/bmj.328.7438.474.
4
Patient choice and complementary medicine.
J R Soc Med. 2004 Jan;97(1):41. doi: 10.1177/014107680409700118.
5
The power of stories over statistics.
BMJ. 2003 Dec 20;327(7429):1424-7. doi: 10.1136/bmj.327.7429.1424.
6
Alosetron and irritable bowel syndrome.
Expert Opin Pharmacother. 2003 Nov;4(11):2089-98. doi: 10.1517/14656566.4.11.2089.
7
New concerns about thalidomide.
Obstet Gynecol. 2002 Jan;99(1):125-8. doi: 10.1016/s0029-7844(01)01662-3.
8
The extent of patients' understanding of the risk of treatments.
Qual Health Care. 2001 Sep;10 Suppl 1(Suppl 1):i14-8. doi: 10.1136/qhc.0100014...
9
Presenting risk information--a review of the effects of "framing" and other manipulations on patient outcomes.
J Health Commun. 2001 Jan-Mar;6(1):61-82. doi: 10.1080/10810730150501413.
10
The total customer relationship in health care: broadening the bandwidth.
Jt Comm J Qual Improv. 1997 May;23(5):245-50. doi: 10.1016/s1070-3241(16)30314-5.
Zotero 插件